Guillain-Barré syndrome (GBS) affects roughly 1.1 to 1.8 people per 100,000 each year worldwide. That translates to somewhere between 85,000 and 140,000 new cases globally per year. It’s rare enough that most doctors will see only a handful of cases in their careers, but common enough that every major hospital encounters it regularly.
Annual Incidence by the Numbers
Studies across Europe and North America consistently report annual incidence rates between 0.84 and 1.91 per 100,000 people. To put that in perspective, in a U.S. city of one million people, you’d expect roughly 10 to 18 new cases each year. The condition is not evenly distributed across age groups, though. After age 50, the rate climbs significantly, reaching 1.7 to 3.3 per 100,000 per year in older adults. Children under 15 have the lowest rates, between 0.34 and 1.34 per 100,000.
Men develop GBS more often than women, and while people of any age can be affected, adults carry a higher overall risk. Some data suggest a seasonal pattern, with more cases occurring in winter months, particularly January, which aligns with the peak season for respiratory infections that often precede GBS.
What Typically Triggers It
About two-thirds of people who develop GBS report some kind of infection in the weeks before symptoms start. The most commonly identified trigger is a bacterial gut infection called Campylobacter jejuni, found in roughly 32% of cases. Other identified triggers include cytomegalovirus (13%), Epstein-Barr virus (10%), and a type of bacterial pneumonia (5%). The remaining cases involve a mix of less common infections or no identifiable trigger at all.
The pattern is consistent: your immune system mounts a response to fight the infection, and in rare cases, it mistakenly attacks the nerves as well. This is why GBS is classified as a post-infectious condition rather than a direct infection of the nervous system.
COVID-19 and Changing Risk Patterns
COVID-19 infection appears to meaningfully increase GBS risk. A large Israeli study tracking over 3 million patients between 2021 and 2022 found that the odds of developing GBS were about six times higher after a COVID-19 infection compared to people who hadn’t been infected. Among the 76 people who developed GBS during the study period, nearly 12% had recently tested positive for COVID-19, compared to just 2.4% of matched controls.
Notably, the same study found no increased risk from mRNA COVID-19 vaccines. Separate CDC analyses did find a possible link between the Johnson & Johnson vaccine (which used a different technology) and GBS, but not with the Pfizer or Moderna vaccines.
Vaccines and GBS Risk
The connection between vaccines and GBS gets more attention than the numbers probably warrant, but the data is worth understanding. For seasonal flu vaccines, when an increased risk has been detected at all, it has consistently been in the range of one to two additional GBS cases per million doses. The 1976 swine flu vaccine carried a somewhat higher risk, roughly one extra case per 100,000 vaccinated people, which led to that campaign being halted.
More recently, the FDA flagged RSV vaccines as carrying a small GBS risk for adults 65 and older. Analysis of Medicare claims data from 2023 to 2024 estimated about 7 to 9 excess GBS cases per million doses, depending on the vaccine brand. These numbers prompted the FDA to require a GBS warning on prescribing information for both approved RSV vaccines, though the absolute risk remains very low.
Who Faces the Highest Risk
Several factors shift your baseline risk. Age is the strongest predictor: people over 50 face roughly double the incidence of younger adults. Being male adds additional risk, though the exact ratio varies between studies. Geographic location matters less than you might expect. Most well-designed surveillance studies in Europe and North America report similar ranges, suggesting GBS occurs at fairly consistent rates across developed countries.
In children, GBS is genuinely uncommon. The annual incidence in kids under 15 tops out at about 1.34 per 100,000, and many studies find rates closer to 0.34 per 100,000, making it roughly two to five times less common than in adults.
Outcomes and Mortality
GBS is serious but survivable in most cases when treated in a setting with modern intensive care. In developed countries, ICU mortality rates for GBS patients range from about 4% to 11%. The picture looks very different in low-resource settings, where mortality can be dramatically higher due to limited access to ventilators and specialized treatment. One multicenter study in Ethiopia, for example, recorded a 19% mortality rate among ICU-admitted GBS patients.
For those who survive, recovery timelines vary widely. Some people regain full function within weeks, while others deal with residual weakness or fatigue for months or even years. The severity of the initial episode, how quickly treatment begins, and the specific subtype of GBS all influence long-term outcomes. The condition follows a characteristic pattern: symptoms worsen over days to weeks, plateau, and then gradually improve, though the “gradually” part can stretch much longer than most patients expect.